Safety Alerts Saves Lives
Safety Alerts  
 
Home Privacy About Us Contact Us Change Preferences

SafetyAlerts
September 10, 2001

Decision Resources Study on Ovarian Cancer

Finds That Premium-Priced Monoclonal Antibodies Will Compete for Market Share

 

Article by: PRNewswire

Decision Resources, Inc., announces the publication of Ovarian Cancer, a new study that evaluates the commercial potential of novel agents to treat this indication. This study presents data on investigational therapies in early- and late-stage development and offers critical strategic analysis to help companies competing in this market to position their products.

Many ovarian cancer drugs are in late-stage development and will become available for use in a larger number of treatment-refractory or drug-resistant patients within the next five years. Drugs that are evaluated in this study include new-generation analogues of currently marketed classes, members of novel classes (angiogenesis inhibitors, inhibitors of drug-resistance processes, vaccines, and immunotherapies), and agents that are marketed for other cancers that are also undergoing trials in ovarian cancer. We find that monoclonal antibodies constitute a particularly dynamic field of development.

Monoclonal Antibodies Are Poised to Have a Significant Impact on the Ovarian Cancer Market

Within the next five years, monoclonal antibodies in late-stage development programs will become available fo One of the reasons for this impressive figure is that a 35-week course of trastuzumab cost nearly $30,000 in 2000, and physicied States and Europe for the adjuvant treatment of ovarian cancer. Pemtumomab is likely to be introduced into the ovarian canceThis study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development
.
 
Selected Recent Recalls


Health Professional:

Did you know?
During 2000 there were over
1050 products recalled in the United
States for safety reasons!

How many did you hear about?

Sign-up for SafetyAlerts by Email -
The free internet newsletter that could
some day literally save your life - or
the life of someone you know.

Safety Alerts compiles comprehensive safety recall information for the United States. SafeMail is a free email service to warn consumers of faulty products and contaminated foods. For complete information regarding current recalls, past recalls and timely product warning notification visit: www.safetyalerts.com.

###

 

The information contained herein has been obtained from sources that the Company believes to be reliable, however, the Company has not independently verified or confirmed the information and the recipient acknowledges that no representations or warranties are being made in connection with the use of the information.